Biliary duct cancer prognosis determination marker, detection primer, kit and application

Abstract

The invention relates to the technical field of gene engineering, and particularly discloses a bile duct cancer prognosis determination marker, a detection primer, a kit and application, the bile ductcancer prognosis determination marker is 5 lncRNAs, and the 5 lncRNAs are respectively HULC, AP000943.4, AC006504.8, AC090114.2 and AL359715.5. A method comprises the following steps: constructing abile duct cancer data set; constructing an LncRNA and gene differential expression profile; establishing an LncRNA related prognosis prediction model; verifying and diagnosing an LncRNA related prognosis prediction model; performing survival prediction that the prognosis LncRNA marker is independent of other clinical pathological characteristic variables; and performing co-expression and functionenrichment analysis: the Spearman correlation coefficient being greater than 0.50 is DPCG related to the LncRNA.

Description

technical field [0001] The invention relates to the technical field of genetic engineering, in particular to a subject title. Background technique [0002] At present, tumor is a major culprit that seriously threatens human health, and the research on the molecular mechanism of tumor malignant progression has always been the focus and difficulty of the academic circle. It has been reported that tumor cells have cell phenotype characteristics such as promotion of proliferation, invasion and metastasis, continuous angiogenesis, immune tolerance and immune escape during growth. Studies have shown that the growth of tumor cells is a complex multi-gene regulation and multi-step, multi-stage development process, including the inactivation of tumor suppressor genes such as p53 and p21 and the activation of proto-oncogenes such as Blc1 and Myc. So far, the pathogenesis of malignant tumors is still not fully understood and needs to be further explored. [0003] Studies have shown t...

AI Technical Summary

Problems solved by technology

[0007] Through the above analysis, the existing problems and defects of the prior art are: the lncRNA gene markers provided by the prior art are poor in judging the prognosis of patients with cholangiocarcinoma after surgery; and the lncRNA gene markers of the prior art select corresponding drugs The effect of adjuvant therapy is not satisfactory, and the effect of individualized treatment for patients with cholangiocarcinoma cannot be achieved

Images